Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of HX008 in advanced solid tumors
CTR20181269Phase 2Completed
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in gastric adenocarcinoma, Nonhematologic neoplasms, mismatch repair deficient solid tumor, sponsored by Taizhou Hanzhong Biomedical. Started Oct 2018; status: completed.
02
Drugs
pucotenlimab
03
Conditions
gastric adenocarcinomaNonhematologic neoplasmsmismatch repair deficient solid tumor
Beyond the preview
Go deeper on CTR20181269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181269.